REYON PHARMACEUTICAL CO., LTD
Financials
Valuation Metrics
REYON PHARMACEUTICAL CO., LTD's Market Cap is ₩1883B. At end of 2025 it was ₩2004B. Ranked #885 of 2,421 in KR market (top 37%), #467 of 781 on KOSPI (top 60%), #95 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 188.28B KRW | KR#885/2,421 Sec#95/231 |
| Revenue | 143.37B KRW | KR#1,212/2,421 Sec#74/231 |
| Net Income | -34.24B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 444.37B KRW | KR#832/2,421 Sec#51/231 |
| Net Assets | 194.87B KRW | KR#962/2,421 Sec#67/231 |
| Employees | 449 | KR#547/2,421 Sec#43/231 |
| Value | ||
| P/B | 0.97x | KR#1,431/2,421 Sec#89/231 |
| P/S | 1.31x | KR#1,563/2,421 Sec#91/231 |
| FCF Yield | -3.43% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -17.57% | KR#2,069/2,421 Sec#161/231 |
| ROA | -7.71% | KR#2,045/2,421 Sec#151/231 |
| Op. Margin | -20.23% | KR#2,125/2,421 Sec#146/231 |
| Revenue Growth | -4.45% | KR#1,746/2,421 Sec#165/231 |
| Financial Health | ||
| Debt Ratio | 128.03% | KR#1,779/2,421 Sec#198/231 |
| Total Debt | 215.01B KRW | KR#494/2,421 Sec#23/231 |
| FCF | -6.46B KRW | KR#1,571/2,421 Sec#125/231 |
| Cash | 7.02B KRW | KR#1,876/2,421 Sec#166/231 |
| Current Ratio | 0.50x | KR#2,141/2,421 Sec#207/231 |
| Dividend | ||
| Div. Growth | 0.48% | KR#686/2,421 Sec#37/231 |
| Performance | ||
| 1Y Return | -13.27% | KR#1,060/2,421 Sec#70/231 |
| 1M Return | 1.71% | KR#1,056/2,421 Sec#79/231 |
| From 52W High | -23.26% | KR#340/2,421 Sec#18/231 |
| 1Y MDD | -22.28% | KR#90/2,421 Sec#5/231 |
| Trading | ||
| Volume | 16,060 shares | KR#1,694/2,421 Sec#165/231 |
| Trading Value | 162.1M KRW | KR#1,351/2,421 Sec#137/231 |
| Foreign Own. | 1.08% | KR#2,006/2,421 Sec#197/231 |
| Per Share | ||
| EPS | -1,842 KRW | KR—/2,421 Sec—/231 |
| BPS | 10,484 KRW | KR#959/2,421 Sec#65/231 |
Company Info
Headquartered in Gangnam-gu, Seoul, E-Yang Pharmaceutical was established in 1964, promoting the domestic production of pharmaceutical raw materials and expanding into new technology business finance in 2017. The company holds various prescription medicines for multiple indications, exclusively supplies original medicines like Optiray, and sells active pharmaceutical ingredients such as Tacrolimus. To become a global bio & chemical pharmaceutical company, it collaborates with bio-ventures on new drug development, with its KGMP-certified Chungju factory driving an R&D business model.